Hansa Medical has resolved to carry out a rights issue of MSEK 246 before deduction of issue related costs. The rights issue is fully guaranteed through subscription undertakings and underwriting. The proceeds from the issue will be used to finance the company’s future research and development activities. In connection herewith, the company also announced that Hansa Medical’s former majority shareholder, Farstorps Gård, has sold some of its holding to certain Swedish and international institutional owners.
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes.. The company’s shares are admitted to trading on Nasdaq First North in Stockholm.
Vinge advised Carnegie which is the financial adviser in connection with the rights issue and sale. The team consists of Peter Bäärnhielm, Dain Nevonen and Sabina Börjesson.